# A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

> **NCT01734382** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 35 (actual)

## Conditions studied

- Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT01734382
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-10
- **Primary completion:** 2019-10-09
- **Final completion:** 2019-10-09
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01734382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01734382, "A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01734382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*